Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials

• Main Authors: Marija Pesic (Author), Thomas Stöhr (Author), Joachim Ossig (Author), Keith Borkett (Author), Martin Donsbach (Author), Van-Anh Dao (Author), Lynn Webster (Author), Frank Schippers (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background and Objectives Remimazolam is a new ultra-short-acting benzodiazepine currently being developed for intravenous use in procedural sedation, general anaesthesia, and intensive care unit sedation. Benzodiazepines represent a drug class associated with drug-facilitated sexual assaul...